Alvogen beats Zohydro patents

Alvogen has convinced a Delaware district judge that two patents protecting Pernix’ Zohydro ER (hydrocodone) extended-release tablets until July 2033 are invalid as obvious and for failure to satisfy the written-description requirement. Pernix plans to appeal.